Curative Biotechnology IncOTC Pink - Current Information:CUBT
- LAST PRICE0.0280
- TODAY'S CHANGE (%)0.0028 (11.1111%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0280 / 0.0252
- Day Range
- 52 Week Range
- Volume5,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CUBT |
|---|---|---|
| 12:00 ET | 5000 | 0.028 |
Mar 31, 2024
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors, from 7:00PM ET on Sunday Mar 31, 2024 by Dow Jones
7:00PM ET on Sunday Mar 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Curative Biotechnology Inc | 15.8M | -2.7x | --- |
Protext Mobility Inc | 15.8M | 0.0x | --- |
Cardio Diagnostics Holdings Inc | 15.6M | -0.9x | --- |
Vaxxinity Inc | 15.4M | -0.3x | --- |
Oncotelic Therapeutics Inc | 16.3M | -2.1x | --- |
NeuroBo Pharmaceuticals Inc | 15.0M | -1.2x | --- |
Company Information
Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.
Contact Information
- Headquarters
- 1825 Nw Corporate Blvd., Suite 110BOCA RATON, FL, United States 33431
- Phone
- 561-907-8990
- Fax
- ---
Executives
- Chairman of the Board, President
- Paul Michaels
- Chief Executive Officer, Chief Financial Officer, General Counsel
- Richard Garr
- Director
- Michael Fish
- Director, Chief Strategy Officer
- Barry Ginsberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 628.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
